Pharmacological and clinical profile of asciminib hydrochloride, a novel first-in-class tyrosine kinase inhibitor specifically targeting ABL myristoyl pocket
Folia Pharmacologica Japonica · 2023
DOI: 10.1254/fpj.22156 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Folia Pharmacologica Japonica, 2023. Verfasst von Jihye Chung und 5 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Pharma KK, Medical Affairs Division. Hauptthemen laut MEDLINE: Antineoplastic Agents, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Novartis Pharma KK, Medical Affairs Division.
- Novartis Pharma KK, Global Drug Development Division.
Zitieren
APA
Chung, J., Ariyoshi, T., Yoneda, T., Kagawa, Y., Kawakita, Y., & Maki, A. (2023). Pharmacological and clinical profile of asciminib hydrochloride, a novel first-in-class tyrosine kinase inhibitor specifically targeting ABL myristoyl pocket. Folia Pharmacologica Japonica. https://doi.org/10.1254/fpj.22156
Vancouver
Chung J, Ariyoshi T, Yoneda T, Kagawa Y, Kawakita Y, Maki A. Pharmacological and clinical profile of asciminib hydrochloride, a novel first-in-class tyrosine kinase inhibitor specifically targeting ABL myristoyl pocket. Folia Pharmacologica Japonica. 2023. doi:10.1254/fpj.22156
BibTeX
@article{Chung2023,
author = {Chung, Jihye and Ariyoshi, Taisuke and Yoneda, Tomohiro and Kagawa, Yusuke and Kawakita, Yasunori and Maki, Akio},
title = {Pharmacological and clinical profile of asciminib hydrochloride, a novel first-in-class tyrosine kinase inhibitor specifically targeting ABL myristoyl pocket},
journal = {Folia Pharmacologica Japonica},
year = {2023},
doi = {10.1254/fpj.22156}
}
EUVIMED